ALVO PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

ALVO ▼ -1.88% at T+20d

SHORT call ✓ call won +1.88% · α vs SPY +5.01% · entry $3.20 → $3.14

Next anchor: T+60d in 7w

Last close $4.17 (close Jun 12) · -30.31% from $3.20 entry (call sign-flipped)

Entry anchored
May 6, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α +0.83%

$3.20

settled 6w ago

T+5d

+14.69%

call -14.69% · α -13.18%

$3.67

settled 5w ago

T+20d

-1.88%

call +1.88% · α +5.01%

$3.14

settled 11d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Alvotech reported Q1 2026 revenue of $105.9M, down 20.3% YoY from $132.8M, due to a production slowdown. Despite the decline, management guided for FY2026 revenue of $650-700M and adjusted EBITDA of $180-220M, implying a recovery. The company also announced a strategic manufacturing agreement with FUJIFILM and expects to resubmit BLAs to the FDA in Q2 2026.

Key Financial Metrics

Guidance

$650M-$700M

initiated

Gross Margin

57%

Actionable Insight

Monitor FDA resubmission in Q2 2026 and Q2 2026 revenue for execution on production normalization. The guidance suggests a strong recovery, but near-term uncertainty remains.

Key Facts

Q1 2026 revenue $105.9M vs $132.8M YoY (-20.3%)
Adjusted EBITDA $24.4M; gross margin 57%
FY2026 guidance: revenue $650-700M, adjusted EBITDA $180-220M
Strategic manufacturing agreement with FUJIFILM Biotechnologies
FDA resubmission of BLAs expected in Q2 2026

Financial Impact

Revenue declined 20% YoY to $105.9M; full-year guidance implies recovery with $650-700M in revenue.

revenueadjusted_ebitdagross_margin

Risk Factors

FDA resubmission delays
Continued production disruptions
Biosimilar competition and pricing pressure

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

75% bullish (12 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3289413

10 reports for ALVO

T+1T+5T+20T+60

33% Hit rate 1 of 3 directional calls best @ T+20▲ +1.88%May 6, 2026

Filters

Reports for ALVO — sortable, filterable
	Type				Now
Jun 8, 2026 7d ago	Press Release NEUTRAL ★ 4/10	$3.55 awaiting T+1	awaiting T+1	—	$4.17 (+17.63%)
Jun 8, 2026 7d ago	Press Release NEUTRAL ★ 4/10	$3.55 awaiting T+1	awaiting T+1	—	$4.17 (+17.63%)
Jun 4, 2026 11d ago	Press Release BULLISH ★ 7/10	$3.74 $3.54	▼ −5.35%	▼ −2.75%	$4.17 (+11.50%)
May 11, 2026 4w ago	Press Release NEUTRAL ★ 4/10	$3.59 $3.55	▼ −1.11%	▼ −0.98%	$4.17 (+16.16%)
May 11, 2026 4w ago	Press Release BULLISH ★ 6/10	$3.59 $3.55	▼ −1.11%	▼ −0.98%	$4.17 (+16.16%)
May 6, 2026 5w ago	Press Release BEARISH ★ 7/10	$3.20 $3.20	· 0.00%	▲ +0.83%	$4.17 (−30.31%)
May 6, 2026 5w ago	Press Release BEARISH ★ 6/10	$3.20 $3.20	· 0.00%	▲ +0.83%	$4.17 (−30.31%)
Apr 24, 2026 7w ago	Press Release NEUTRAL ★ 2/10	$3.38 $3.30	▼ −2.37%	▼ −2.53%	$4.17 (+23.37%)
Apr 24, 2026 7w ago	Press Release NEUTRAL ★ 3/10	$3.38 $3.30	▼ −2.37%	▼ −2.53%	$4.17 (+23.37%)
Mar 4, 2026 14w ago	Press Release NEUTRAL ★ 3/10	$3.89 $4.16	▲ +6.94%	▲ +7.51%	$4.17 (+7.20%)

US Market Status

Market Closed — Opens in 5h 8m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access